A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. - Collier KA; Valencia H; Newton H; Hade EM; Sborov DW; Cavaliere R; Poi M; Phelps MA; Liva SG; Coss CC; Wang J; Khountham S; et al. (Cancer chemotherapy and pharmacology, 2021)